Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety
- 3 October 2005
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 6 (12), 2117-2140
- https://doi.org/10.1517/14656566.6.12.2117
Abstract
The discovery of two distinct isoenzymes of COX has led to the development and clinical introduction of COX-2 inhibitors with increased selectivity onto the market. Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, and is a preferential inhibitor of COX-2, demonstrating effectiveness with anti-inflammatory, analgesic and antipyretic activity. Meloxicam is therapeutically utilised in the management of osteoarthritis and rheumatoid arthritis. Trials have examined the risk of gastrointestinal ulceration of meloxicam when compared with traditional non-specific COX-inhibiting NSAIDs with mixed results; meloxicam seems to have a greater gastrointestinal risk than the highly specific COX-2 NSAIDs. Meloxicam has a plasma half-life of approximately 20 h and is convenient for once daily administration. Neither moderate renal nor hepatic insufficiency significantly alters the pharmacokinetics of meloxicam in short-term studies. Furthermore, dose adjustment is not required in the elderly. Recent drug-drug interaction studies have demonstrated that meloxicam interacts with some medications, including cholestyramine, lithium and some inhibitors of cytochrome P450 -2C9 and -3A4. Consequently, increased clinical vigilance should be maintained when coprescribing some medications with meloxicam. Concentration-dependent therapeutic and toxicological effects have yet to be extensively elucidated for meloxicam. Long-term safety in various organ systems, especially in the heart and vascular system and with concomitant drug administration, remains to be proven. The pharmacokinetics of meloxicam enables once daily application, which increases compliance compared with some shorter acting NSAIDs; however, long-term clinical data clearly demonstrating safety and efficacy advantages are lacking.Keywords
This publication has 48 references indexed in Scilit:
- New Effort to Develop Molecular Tools for Early Cancer Detection Under WayPublished by American Medical Association (AMA) ,2005
- Pharmacokinetics of Meloxicam in Patients With Juvenile Rheumatoid ArthritisThe Journal of Clinical Pharmacology, 2004
- In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide familiesEuropean Journal of Pharmacology, 2004
- Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care populationAmerican Journal of Hospice and Palliative Medicine®, 2003
- MeloxicamExpert Opinion on Pharmacotherapy, 2002
- Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilageBritish Journal of Pharmacology, 2000
- Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4Xenobiotica, 1998
- MeloxicamDrugs, 1996
- Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal toleranceInflammation Research, 1995
- Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID)Inflammation Research, 1991